Latest Pharma Insights
MiniMed Targets 10% Growth With Three Launches And Abbott Sensor Deal In Play
The former Medtronic Diabetes unit posted strong international numbers and a pipeline of new products, while US growth lagged on a self-inflicted timing issue tied to an early regulatory win.
Medtech Insight - June 4, 2026
The former Medtronic Diabetes unit posted strong international numbers and a pipeline of new products, while US growth lagged on a self-inflicted timing issue tied to an early regulatory win.
Medtech Insight - June 4, 2026
Autobahn’s Small Bipolar Depression Trial Shows Promise Ahead Of Bigger MDD Readout
Phase II data in bipolar I and II has bolstered private firm Autobahn’s confidence in an upcoming 220-patient depression trial readout for thyroid hormone receptor agonist elunetirom.
Scrip - June 4, 2026
Phase II data in bipolar I and II has bolstered private firm Autobahn’s confidence in an upcoming 220-patient depression trial readout for thyroid hormone receptor agonist elunetirom.
Scrip - June 4, 2026
Lilly Is Just Getting Started With Zepbound In Autoimmune Disease
The firm’s immunology leader Mark Genovese sees more scope for Zepbound and its next-generation incretins in treating a wide range of autoimmune diseases.
Scrip - June 4, 2026
The firm’s immunology leader Mark Genovese sees more scope for Zepbound and its next-generation incretins in treating a wide range of autoimmune diseases.
Scrip - June 4, 2026
Few Share Price Winners Post ASCO 2026
Biotech share movements in the wake of ASCO ’26 reveal mostly pain for the sector, along with a handful of gainers including Legend Biotech.
Scrip - June 4, 2026
Biotech share movements in the wake of ASCO ’26 reveal mostly pain for the sector, along with a handful of gainers including Legend Biotech.
Scrip - June 4, 2026
ASCO 2026: Standout Wins And Strategic Shifts
Revolution Medicines' PDAC survival data headlined the recent ASCO meeting, alongside practice-changing readouts from J&J and Lilly, a crowded ADC and bispecific field, and Chinese biotechs delivering increasingly competitive results.
In Vivo - June 4, 2026
Revolution Medicines' PDAC survival data headlined the recent ASCO meeting, alongside practice-changing readouts from J&J and Lilly, a crowded ADC and bispecific field, and Chinese biotechs delivering increasingly competitive results.
In Vivo - June 4, 2026
Canada Drops Need For Biosimilar Comparative Clinical Efficacy Studies
Health Canada's elimination of comparative clinical efficacy studies for biosimilar products aligns with steps being taken by the US and EU drug regulators.
Generics Bulletin - June 4, 2026
Health Canada's elimination of comparative clinical efficacy studies for biosimilar products aligns with steps being taken by the US and EU drug regulators.
Generics Bulletin - June 4, 2026
US Supreme Court Backs Hikma In Landmark Skinny-Label Generic Ruling
In a long-awaited ruling over skinny-label generic carve-outs and induced infringement, the US Supreme Court has come down on the side of the generics industry by backing Hikma over Amarin in the culmination of the pair’s long-running litigation over Vascepa.
Generics Bulletin - June 4, 2026
In a long-awaited ruling over skinny-label generic carve-outs and induced infringement, the US Supreme Court has come down on the side of the generics industry by backing Hikma over Amarin in the culmination of the pair’s long-running litigation over Vascepa.
Generics Bulletin - June 4, 2026
Alnylam, Inceptive Sign AI-RNAi Drug Discovery Deal Worth Up To $2bn
The deal highlights Alnylam's push to augment its RNAi discovery engine with AI as it expands beyond its current portfolio and advances its long-term pipeline growth strategy.
Scrip - June 4, 2026
The deal highlights Alnylam's push to augment its RNAi discovery engine with AI as it expands beyond its current portfolio and advances its long-term pipeline growth strategy.
Scrip - June 4, 2026
GLP-1: Consumer Health Industry Should Be Looking Ahead To Future Rx-To-OTC Switch
The consumer health industry should be positioning now for a future GLP-1 Rx-to-OTC switch, said former AESGP president Birgit Schuhbauer at the association's Annual Meeting in Berlin.
HBW Insight - June 4, 2026
The consumer health industry should be positioning now for a future GLP-1 Rx-to-OTC switch, said former AESGP president Birgit Schuhbauer at the association's Annual Meeting in Berlin.
HBW Insight - June 4, 2026
Executives On The Move: Two New CEOs And Five CMOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Retension Pharmaceuticals, Allogene Therapeutics and Biote, plus Nuvalent gets a new chief international officer from Blueprint Medicines.
Scrip - June 4, 2026
Recent moves in the industry include C-suite changes at Retension Pharmaceuticals, Allogene Therapeutics and Biote, plus Nuvalent gets a new chief international officer from Blueprint Medicines.
Scrip - June 4, 2026
Venture Life Secures ‘Immediate Scale And Presence’ In US With OrganiCare Acquisition
UK-based Venture Life acquires Austin's OrganiCare and gains scalable platform for growth in the women’s health category and US OTC market more broadly.
HBW Insight - June 4, 2026
UK-based Venture Life acquires Austin's OrganiCare and gains scalable platform for growth in the women’s health category and US OTC market more broadly.
HBW Insight - June 4, 2026
Medtronic Bets On Tuck-In Deals And CAS Momentum To Sustain Growth Into Fiscal 2027
The medtech giant closed out fiscal 2026 with double-digit cardiovascular gains and a string of acquisitions, while bracing for $250m in tariff headwinds.
Medtech Insight - June 4, 2026
The medtech giant closed out fiscal 2026 with double-digit cardiovascular gains and a string of acquisitions, while bracing for $250m in tariff headwinds.
Medtech Insight - June 4, 2026
Fractyl’s One-Time Procedure Shows Durable Weight Control A Year After GLP-1 Withdrawal
Open-label data show 78% weight-loss retention at one year post-GLP-1 discontinuation, as Fractyl advances toward a De Novo filing and reimbursement synchronized under the new RAPID pathway.
Medtech Insight - June 4, 2026
Open-label data show 78% weight-loss retention at one year post-GLP-1 discontinuation, as Fractyl advances toward a De Novo filing and reimbursement synchronized under the new RAPID pathway.
Medtech Insight - June 4, 2026
Hikma Overtakes US Xeljanz Exclusivity As Tablets Loom Larger
Hikma’s launch of a generic version of Xeljanz oral solution, though small in scale, highlights Slayback’s first-filer status, widening generic competition and the much bigger tablet opportunity now opening up.
Generics Bulletin - June 4, 2026
Hikma’s launch of a generic version of Xeljanz oral solution, though small in scale, highlights Slayback’s first-filer status, widening generic competition and the much bigger tablet opportunity now opening up.
Generics Bulletin - June 4, 2026
Endo Creditors Fight On In $4bn Par-TPG Dispute
A bankruptcy judge has let Endo’s trustee keep pursuing Par’s former owner TPG over allegations that Endo significantly overpaid for Par in 2015, while dismissing opioid contribution claims and claims against former Par executives.
Generics Bulletin - June 4, 2026
A bankruptcy judge has let Endo’s trustee keep pursuing Par’s former owner TPG over allegations that Endo significantly overpaid for Par in 2015, while dismissing opioid contribution claims and claims against former Par executives.
Generics Bulletin - June 4, 2026
EU Urban Wastewater ‘Producer Pays’ Provisions Could Fall Before Implementation
At the 62nd AESGP Annual Meeting, Squire Patton Boggs' Manon Ombredane sets out the four simultaneous legal challenges to the UWWTD's extended producer responsibility provisions and the timelines that could see them struck down before member states are required to transpose them.
HBW Insight - June 4, 2026
At the 62nd AESGP Annual Meeting, Squire Patton Boggs' Manon Ombredane sets out the four simultaneous legal challenges to the UWWTD's extended producer responsibility provisions and the timelines that could see them struck down before member states are required to transpose them.
HBW Insight - June 4, 2026
‘Too Badly Designed To Work’ – Industry Lays Into EU Urban Wastewater Directive
At the 62nd AESGP Annual Meeting in Berlin, president Jonathan Workman and Pharma Deutschland's Lutz Boden line up against the EU Urban Wastewater Treatment Directive as PwC analysis suggests industry may be overcharged by a factor of 50.
HBW Insight - June 4, 2026
At the 62nd AESGP Annual Meeting in Berlin, president Jonathan Workman and Pharma Deutschland's Lutz Boden line up against the EU Urban Wastewater Treatment Directive as PwC analysis suggests industry may be overcharged by a factor of 50.
HBW Insight - June 4, 2026
ASCO: DAC Throws Hat In SCLC Ring With Anti-CD56 ADC
Phase I data show Hangzhou DAC’s CD56-targeting antibody-drug conjugate DXC006 yielded an unconfirmed 75% objective response rate in second-line small cell lung cancer, while CD56-related toxicities were low.
Scrip - June 4, 2026
Phase I data show Hangzhou DAC’s CD56-targeting antibody-drug conjugate DXC006 yielded an unconfirmed 75% objective response rate in second-line small cell lung cancer, while CD56-related toxicities were low.
Scrip - June 4, 2026
The CEO Who Wants to Make Tacrolimus History
Eledon CEO David-Alexandre Gros is advancing tegoprubart, a CD40L blocker showing dramatically fewer side effects than tacrolimus, toward Phase III kidney transplant trials and beyond.
In Vivo - June 4, 2026
Eledon CEO David-Alexandre Gros is advancing tegoprubart, a CD40L blocker showing dramatically fewer side effects than tacrolimus, toward Phase III kidney transplant trials and beyond.
In Vivo - June 4, 2026
Spain’s Ona Advances ADCs Into Clinic After Cash Boost
Fundraising is tricky, especially for European biotechs, but the Barcelona-based firm has just closed an oversubscribed series B which brought in over $86m.
Scrip - June 4, 2026
Fundraising is tricky, especially for European biotechs, but the Barcelona-based firm has just closed an oversubscribed series B which brought in over $86m.
Scrip - June 4, 2026
US CIR To Revisit Kojic Acid In Light Of EU Restriction; Welcomes Panel Member
The Cosmetic Ingredient Review Expert Panel plans to review the safety of kojic acid and welcomes Dr. Bruce Brod as the newest panel member in advance of its 176th meeting on June 15-16.
HBW Insight - June 4, 2026
The Cosmetic Ingredient Review Expert Panel plans to review the safety of kojic acid and welcomes Dr. Bruce Brod as the newest panel member in advance of its 176th meeting on June 15-16.
HBW Insight - June 4, 2026
Autobahn’s Small Bipolar Depression Trial Shows Promise Ahead Of Bigger MDD Readout
Phase II data in bipolar I and II has bolstered private firm Autobahn’s confidence in an upcoming 220-patient depression trial readout for thyroid hormone receptor agonist elunetirom.
Scrip - June 4, 2026
Phase II data in bipolar I and II has bolstered private firm Autobahn’s confidence in an upcoming 220-patient depression trial readout for thyroid hormone receptor agonist elunetirom.
Scrip - June 4, 2026
Lilly Is Just Getting Started With Zepbound In Autoimmune Disease
The firm’s immunology leader Mark Genovese sees more scope for Zepbound and its next-generation incretins in treating a wide range of autoimmune diseases.
Scrip - June 4, 2026
The firm’s immunology leader Mark Genovese sees more scope for Zepbound and its next-generation incretins in treating a wide range of autoimmune diseases.
Scrip - June 4, 2026
Few Share Price Winners Post ASCO 2026
Biotech share movements in the wake of ASCO ’26 reveal mostly pain for the sector, along with a handful of gainers including Legend Biotech.
Scrip - June 4, 2026
Biotech share movements in the wake of ASCO ’26 reveal mostly pain for the sector, along with a handful of gainers including Legend Biotech.
Scrip - June 4, 2026
Alnylam, Inceptive Sign AI-RNAi Drug Discovery Deal Worth Up To $2bn
The deal highlights Alnylam's push to augment its RNAi discovery engine with AI as it expands beyond its current portfolio and advances its long-term pipeline growth strategy.
Scrip - June 4, 2026
The deal highlights Alnylam's push to augment its RNAi discovery engine with AI as it expands beyond its current portfolio and advances its long-term pipeline growth strategy.
Scrip - June 4, 2026
Executives On The Move: Two New CEOs And Five CMOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Retension Pharmaceuticals, Allogene Therapeutics and Biote, plus Nuvalent gets a new chief international officer from Blueprint Medicines.
Scrip - June 4, 2026
Recent moves in the industry include C-suite changes at Retension Pharmaceuticals, Allogene Therapeutics and Biote, plus Nuvalent gets a new chief international officer from Blueprint Medicines.
Scrip - June 4, 2026
ASCO: DAC Throws Hat In SCLC Ring With Anti-CD56 ADC
Phase I data show Hangzhou DAC’s CD56-targeting antibody-drug conjugate DXC006 yielded an unconfirmed 75% objective response rate in second-line small cell lung cancer, while CD56-related toxicities were low.
Scrip - June 4, 2026
Phase I data show Hangzhou DAC’s CD56-targeting antibody-drug conjugate DXC006 yielded an unconfirmed 75% objective response rate in second-line small cell lung cancer, while CD56-related toxicities were low.
Scrip - June 4, 2026
Spain’s Ona Advances ADCs Into Clinic After Cash Boost
Fundraising is tricky, especially for European biotechs, but the Barcelona-based firm has just closed an oversubscribed series B which brought in over $86m.
Scrip - June 4, 2026
Fundraising is tricky, especially for European biotechs, but the Barcelona-based firm has just closed an oversubscribed series B which brought in over $86m.
Scrip - June 4, 2026
MiniMed Targets 10% Growth With Three Launches And Abbott Sensor Deal In Play
The former Medtronic Diabetes unit posted strong international numbers and a pipeline of new products, while US growth lagged on a self-inflicted timing issue tied to an early regulatory win.
Medtech Insight - June 4, 2026
The former Medtronic Diabetes unit posted strong international numbers and a pipeline of new products, while US growth lagged on a self-inflicted timing issue tied to an early regulatory win.
Medtech Insight - June 4, 2026
Medtronic Bets On Tuck-In Deals And CAS Momentum To Sustain Growth Into Fiscal 2027
The medtech giant closed out fiscal 2026 with double-digit cardiovascular gains and a string of acquisitions, while bracing for $250m in tariff headwinds.
Medtech Insight - June 4, 2026
The medtech giant closed out fiscal 2026 with double-digit cardiovascular gains and a string of acquisitions, while bracing for $250m in tariff headwinds.
Medtech Insight - June 4, 2026
Fractyl’s One-Time Procedure Shows Durable Weight Control A Year After GLP-1 Withdrawal
Open-label data show 78% weight-loss retention at one year post-GLP-1 discontinuation, as Fractyl advances toward a De Novo filing and reimbursement synchronized under the new RAPID pathway.
Medtech Insight - June 4, 2026
Open-label data show 78% weight-loss retention at one year post-GLP-1 discontinuation, as Fractyl advances toward a De Novo filing and reimbursement synchronized under the new RAPID pathway.
Medtech Insight - June 4, 2026
GLP-1: Consumer Health Industry Should Be Looking Ahead To Future Rx-To-OTC Switch
The consumer health industry should be positioning now for a future GLP-1 Rx-to-OTC switch, said former AESGP president Birgit Schuhbauer at the association's Annual Meeting in Berlin.
HBW Insight - June 4, 2026
The consumer health industry should be positioning now for a future GLP-1 Rx-to-OTC switch, said former AESGP president Birgit Schuhbauer at the association's Annual Meeting in Berlin.
HBW Insight - June 4, 2026
Venture Life Secures ‘Immediate Scale And Presence’ In US With OrganiCare Acquisition
UK-based Venture Life acquires Austin's OrganiCare and gains scalable platform for growth in the women’s health category and US OTC market more broadly.
HBW Insight - June 4, 2026
UK-based Venture Life acquires Austin's OrganiCare and gains scalable platform for growth in the women’s health category and US OTC market more broadly.
HBW Insight - June 4, 2026
EU Urban Wastewater ‘Producer Pays’ Provisions Could Fall Before Implementation
At the 62nd AESGP Annual Meeting, Squire Patton Boggs' Manon Ombredane sets out the four simultaneous legal challenges to the UWWTD's extended producer responsibility provisions and the timelines that could see them struck down before member states are required to transpose them.
HBW Insight - June 4, 2026
At the 62nd AESGP Annual Meeting, Squire Patton Boggs' Manon Ombredane sets out the four simultaneous legal challenges to the UWWTD's extended producer responsibility provisions and the timelines that could see them struck down before member states are required to transpose them.
HBW Insight - June 4, 2026
‘Too Badly Designed To Work’ – Industry Lays Into EU Urban Wastewater Directive
At the 62nd AESGP Annual Meeting in Berlin, president Jonathan Workman and Pharma Deutschland's Lutz Boden line up against the EU Urban Wastewater Treatment Directive as PwC analysis suggests industry may be overcharged by a factor of 50.
HBW Insight - June 4, 2026
At the 62nd AESGP Annual Meeting in Berlin, president Jonathan Workman and Pharma Deutschland's Lutz Boden line up against the EU Urban Wastewater Treatment Directive as PwC analysis suggests industry may be overcharged by a factor of 50.
HBW Insight - June 4, 2026
US CIR To Revisit Kojic Acid In Light Of EU Restriction; Welcomes Panel Member
The Cosmetic Ingredient Review Expert Panel plans to review the safety of kojic acid and welcomes Dr. Bruce Brod as the newest panel member in advance of its 176th meeting on June 15-16.
HBW Insight - June 4, 2026
The Cosmetic Ingredient Review Expert Panel plans to review the safety of kojic acid and welcomes Dr. Bruce Brod as the newest panel member in advance of its 176th meeting on June 15-16.
HBW Insight - June 4, 2026
Canada Drops Need For Biosimilar Comparative Clinical Efficacy Studies
Health Canada's elimination of comparative clinical efficacy studies for biosimilar products aligns with steps being taken by the US and EU drug regulators.
Generics Bulletin - June 4, 2026
Health Canada's elimination of comparative clinical efficacy studies for biosimilar products aligns with steps being taken by the US and EU drug regulators.
Generics Bulletin - June 4, 2026
US Supreme Court Backs Hikma In Landmark Skinny-Label Generic Ruling
In a long-awaited ruling over skinny-label generic carve-outs and induced infringement, the US Supreme Court has come down on the side of the generics industry by backing Hikma over Amarin in the culmination of the pair’s long-running litigation over Vascepa.
Generics Bulletin - June 4, 2026
In a long-awaited ruling over skinny-label generic carve-outs and induced infringement, the US Supreme Court has come down on the side of the generics industry by backing Hikma over Amarin in the culmination of the pair’s long-running litigation over Vascepa.
Generics Bulletin - June 4, 2026
Hikma Overtakes US Xeljanz Exclusivity As Tablets Loom Larger
Hikma’s launch of a generic version of Xeljanz oral solution, though small in scale, highlights Slayback’s first-filer status, widening generic competition and the much bigger tablet opportunity now opening up.
Generics Bulletin - June 4, 2026
Hikma’s launch of a generic version of Xeljanz oral solution, though small in scale, highlights Slayback’s first-filer status, widening generic competition and the much bigger tablet opportunity now opening up.
Generics Bulletin - June 4, 2026
Endo Creditors Fight On In $4bn Par-TPG Dispute
A bankruptcy judge has let Endo’s trustee keep pursuing Par’s former owner TPG over allegations that Endo significantly overpaid for Par in 2015, while dismissing opioid contribution claims and claims against former Par executives.
Generics Bulletin - June 4, 2026
A bankruptcy judge has let Endo’s trustee keep pursuing Par’s former owner TPG over allegations that Endo significantly overpaid for Par in 2015, while dismissing opioid contribution claims and claims against former Par executives.
Generics Bulletin - June 4, 2026
ASCO 2026: Standout Wins And Strategic Shifts
Revolution Medicines' PDAC survival data headlined the recent ASCO meeting, alongside practice-changing readouts from J&J and Lilly, a crowded ADC and bispecific field, and Chinese biotechs delivering increasingly competitive results.
In Vivo - June 4, 2026
Revolution Medicines' PDAC survival data headlined the recent ASCO meeting, alongside practice-changing readouts from J&J and Lilly, a crowded ADC and bispecific field, and Chinese biotechs delivering increasingly competitive results.
In Vivo - June 4, 2026
The CEO Who Wants to Make Tacrolimus History
Eledon CEO David-Alexandre Gros is advancing tegoprubart, a CD40L blocker showing dramatically fewer side effects than tacrolimus, toward Phase III kidney transplant trials and beyond.
In Vivo - June 4, 2026
Eledon CEO David-Alexandre Gros is advancing tegoprubart, a CD40L blocker showing dramatically fewer side effects than tacrolimus, toward Phase III kidney transplant trials and beyond.
In Vivo - June 4, 2026